AAGPs™ were invented by Dr. Geraldine-Castelot-Deliencourt and developed and protected by patents in partnership with the Institute for Scientific Application (INSA) of France. For her work in this area Dr. Castelot-Deliencourt was honored in 2006 with France’s highest award for scientific accomplishment – the Francinov Award.

Cells are the basic independent units of life. Cell clusters that perform similar functions are tissues and organs. Cell function and survival is constantly challenged as cells, and tissues and organs, are subjected to a multitude of environmental stresses, aging, various diseases and genetic disorders.

Cell therapy is a field of medicine that uses cells to repair tissues and organs that have been damaged by human disease or to generate new tissues with desired functional activities. Medical science is making considerable progress in research and developing therapies using embryonic and adult stem cells.

At the same time the use of blood component cells in transfusions and organ transplants continue to be an important part of many medical treatments. Cells, tissues and organs all need to survive with enhanced health for these procedures to be more effective.

ProtoKinetix’ anti-aging glycopeptides, trademarked as AAGPs™, have demonstrated in tests the ability to enhance the health and extend the life of biologically sensitive cells which have been subjected to acute stress conditions under laboratory controlled protocols. AAGPs™ have shown to be stable and non-toxic.

ProtoKinetix owns the world-wide rights to this family of anti-aging glycopeptides.

Since inception in 2004, ProtoKinetix has primarily focused on scientific research, but the company is now in the process of directing major efforts to the practical side of commercialization. The commercial applications for AAGPs™ in large markets such as skincare/cosmetic products and targeted health care solutions are numerous. ProtoKinetix is currently working with leading businesses to bring AAGP™ to market.

DECEMBER 07, 2011
ITALIAN LABORATORY EXPANDS PROTOKINETIX' MARKET FOR AAGP™

SEPTEMBER 21, 2011
PROTOKINETIX RECEIVES EXCELLENT RESULTS FROM THE UNIVERSITY OF BRITISH COLUMBIA EYE INFLAMMATION STUDY

AUGUST 18, 2011
PROTOKINETIX LAUNCHES SALES OF AAGP™ AS A TOOL TO PROTECT CELLS IN RESEARCH

JULY 25, 2011
THE UNIVERSITY OF BRITISH COLUMBIA STUDIES THE DEVELOPMENT OF PROTOKINETIX' AAGP™ ANTI-INFLAMMATORY FOR THE $20-BILLION EYE TREATMENT MARKET

MAY 04, 2011
PROTOKINETIX PRESIDENT AND CEO TO BE INTERVIEWED LIVE